Navigation Links
Clinical Study Data Indicates that Celliant Reduces Pain
Date:6/25/2009

A just completed clinical study proves that revolutionary technical performance fiber actually reduces pain when worn in garments or slept on in bedding. Already proven to increase oxygen levels in the body, data from a new clinical study published in online journal BioMed Central (www.BioMedCentral.com) supports claims that Celliant reduces pain.

Santa Monica, CA (PRWEB) June 25, 2009 -- Already proven to increase oxygen levels in the body, data from a new clinical study published in online journal BioMedCentral.com supports claims that Celliant reduces pain.

Celliant is a specially formulated technical performance fiber designed to enhance oxygen levels in the body, aiding in comfort, healing, performance and overall wellness. Data analysis from a clinical study conducted by Robyn MB York and Ian L. Gordon, research scientists affiliated with Long Beach VA Healthcare System and UCI Medical Center, shows that the material also has potent pain relief capabilities. In a double blind study using measurement techniques successfully employed in FDA-supervised clinical trials of pain relief medications, the magnitude of pain relief reported by participants using products enhanced with Celliant was significantly greater than that reported by participants using placebo products. Hologenix, LLC, the company behind Celliant, sponsored the trials.

"We have completed a properly designed clinical trial which shows strong results in favor of Celliant," explains Seth Casden, CEO of Hologenix, LLC. "The results are statistically significant, providing clinical proof that products enhanced with Celliant actually reduce pain."

These results have obvious implications for the health and medical markets. However, Hologenix believes a broader market for their pain relieving textile exists.

"To date, much of the research conducted on Celliant has been limited to patients with diabetes, or some form of vascular impairment," explains Casden. "However, many individuals have trouble staying active because of chronic pain--virtually everyone suffers from some sort of ache or pain during their life."

In fact, this most recent study included subjects who suffered from diabetic neuropathic pain as well as a second group of non-diabetic subjects. Both groups experienced significant pain relief. The data showing a greater reduction in pain with Celliant was sufficiently strong that the research team is conducting a second, follow-up study to further measure the pain reduction and healing characteristics of Celliant.

"Personally, I was very surprised by the results. In doing these studies, you often hope for a positive result but, in this case, the data points overwhelmingly to Celliant reducing pain," stated Dr. Ian L. Gordon, PhD and head of Vascular Surgery at Long Beach VA Medical Center. "What we have here is a material that can be incorporated into any number of products--garments, bedding, socks, bandages, athletic wear--to non-invasively reduce pain. It's a very exciting moment for us as research scientists and for the medical and health community at large."

The technology behind Celliant is based on years of research regarding the effect of certain wavelengths of light on the body and wound healing. Past studies have shown that light can be used to reduce pain, speed healing, increase energy and improve overall wellness. Celliant is a polymer fiber containing optically active micro-particles - a proprietary mixture of natural materials - which scatter and reflect visible and near infrared light. Products constructed with such optically modified fibers are designed to scatter and reflect light and energy onto the underlying tissue and skin. Numerous anecdotal reports from patients with a variety of chronic pain syndromes indicate that wearing garments or sleeping on bedding containing Celliant led to dramatic improvement or complete resolution of pain. The goal of this study was to scientifically confirm and measure these results. The full study can be found here: Celliant Pain Study.

Hologenix, LLC, is currently conducting three additional clinical studies to further measure the effects of Celliant on sleep, athletic performance and health.

About Celliant
Celliant is a specially formulated fiber that is knit or woven into fabrics used in garments and bedding materials. Products containing Celliant have been clinically proven to enhance oxygen levels in the body and reduce pain. Increased oxygen levels have been clinically proven to relieve pain, promote quicker healing, improve sleep quality, heighten athletic performance and improve overall wellness. For more information about products that include Celliant, how Celliant works, or studies that have been conducted on Celliant, please visit www.celliant.com.

Products enhanced with Celliant have been clinically proven to relieve pain, increase comfort and aid in healing by increasing oxygen levels and helping to regulate body temperature. Celliant is now available in a variety of products for the sleep, sport, health and life markets.

About Hologenix
Hologenix, LLC, maker of Celliant, is committed to creating, discovering and marketing products that enhance people's lives through pain relief, increased comfort and improved overall well-being. The research that led to the creation of Celliant began in the 1990s when a team of pioneers in the field of alternative medicine visited Asia and observed the use of several natural substances that were thought to have a positive effect on health. After seven years of research and study, the team was able to integrate some of these materials into fabrics that could be made into apparel, bedding and medical products. Hologenix was founded in order to commercialize and bring this material, known as Celliant, to market. The Celliant formulation is patent protected.

###

Read the full story at http://www.prweb.com/releases/Celliant/PainStudy/prweb2567504.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical Study Data Indicates that Celliant Reduces Pain
(Date:2/10/2016)... ... February 10, 2016 , ... ... health care communications company offering education, research and medical media, has launched ... specialists working in infectious diseases. , As the all-inclusive resource for infectious ...
(Date:2/10/2016)... Walton Beach, Florida (PRWEB) , ... February 10, ... ... the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at the ... platform, MetLoop has “put the power of the world's most advanced weather technology ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , a ... partnered with Heart City Health Center to improve access to language ... City Health Center has provided the Elkhart community with access to high quality, ...
(Date:2/10/2016)... ... 10, 2016 , ... Compliancy Group LLC is pleased to ... throughout the country. The Guard was specifically designed to handle each element required ... regulatory updates, and compliance coaching. , In addition to meeting the compliance needs ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Emergency rooms provide ... to find. Unfortunately, this can leave patients with dental emergencies at risk of losing ... now offering emergency dental care. , Common dental emergencies include:, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... SEATTLE , Feb. 10, 2016  Resolve ... potentially transformative new approaches to the treatment of ... completion of a multiple ascending dose study in ... lead compound RSLV-132. --> ... double-blind, placebo-controlled multiple ascending dose study of RSLV-132 ...
(Date:2/10/2016)...  Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" ... of its issued and outstanding shares of common stock ... 11, 2016. The Company,s common stock will trade on ... temporary ticker symbol "RCHAD". After 20 trading days, the ... (RCHA).  --> --> ...
(Date:2/10/2016)... Tenn. , Feb. 10, 2016 /PRNewswire/ ... of Nursing received an in-kind gift ... of a VeinViewer® Vision vein finder for ... will help students as they learn how ... combining technology with traditional technique. ...
Breaking Medicine Technology: